Clinical trials: Stage II Breast Carcinoma
Breast Neoplasms, Dermatitis
Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy
The investigators conduct this phase II study of EGCG therapy protection of the skin from damage induced by radiotherapy in breast cancer.
- Conditions
- Breast Neoplasms, Dermatitis, Prevention & Control, Epigallocatechin Gallate
- Trial name
- NCT02580279
- Testing
- EGCG
- Volunteers
- 68 people
- Sponsor
- Shandong Cancer Hospital and Institute
Locally Advanced HER2-negative Breast Cancer
Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer
The purpose of this study is to determine whether weekly paclitaxel followed by weekly doxorubicin plus daily oral cyclophosphamide without granulocyte colony-stimulating factor (G-CSF) is feasible in the treatment of locally…
- Trial name
- TAME-01 (NCT01329627)
- Testing
- Paclitaxel/doxorubicin/cyclophosphamide
- Where
- Brazil
- Volunteers
- 12 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer
This phase II trial studies how well veliparib with or without carboplatin works in treating patients with stage III or IV breast cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma
- Trial name
- NCT01149083
- Testing
- Biopsy, Biospecimen Collection, Carboplatin
- Where
- 23 sites in United States, Canada
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Chemotherapy Plus Surgery in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining surgery with chemotherapy may kill more tumor cells.
- Trial name
- NCT00003013
- Testing
- CMF regimen, cyclophosphamide, doxorubicin hydrochloride
- Where
- 28 sites in Austria, Czechia and 9 more
- Volunteers
- 450 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Breast Cancer, Proton Therapy
Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy
Breast-conserving surgery (BCS) followed by whole-breast irradiation (WBI) remains the standard therapeutic approach for early-stage breast cancer.
- Trial name
- UPH-BC (NCT07135661)
- Testing
- moderate hypofractionated proton radiotherapy, ultra-hypofractionated proton radiotherapy
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
Breast Cancer
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00769470
- Testing
- trastuzumab, carboplatin, docetaxel
- Where
- 15 sites in United States
- Volunteers
- 18 people
- Sponsor
- Translational Oncology Research International
Breast Cancer, Metastatic Breast Cancer
Trastuzumab and Vinorelbine in Advanced Breast Cancer
The purpose of this research study is to see what effects trastuzumab in combination with vinorelbine has on breast cancer when the participant has circulating tumor cells that are positive for the protein called HER2.
- Trial name
- NCT01185509
- Testing
- trastuzumab, vinorelbine
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Malignant Neoplasm, Breast Cancer
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases.
- Conditions
- Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
- Trial name
- NCT04503265
- Testing
- AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II
- Where
- 4 sites in United States
- Volunteers
- 122 people
- Sponsor
- AtlasMedx, Incorporated
Breast Cancer
Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer
The primary purpose of this study is to help answer the following research questions: whether the chemotherapy combination therapy Pemetrexed-Carboplatin or Gemcitabine-Vinorelbine can help participants with advanced breast…
- Trial name
- NCT00325234
- Testing
- Pemetrexed, Carboplatin, Gemcitabine
- Where
- 22 sites in Germany, Italy and 3 more
- Volunteers
- 135 people
- Sponsor
- Eli Lilly and Company
Breast Neoplasms
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
Pemetrexed is a multi-targeted anti-folate, that is used for non-small cell lung cancer and mesothelioma. There are several clinical studies of pemetrexed in breast cancer, but these are largely done before the wide use of…
- Trial name
- NCT03242616
- Testing
- Pemetrexed + Vinorelbine, Vinorelbine
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Seoul National University Hospital
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement.
- Conditions
- Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma
- Trial name
- PROFFi (NCT06113016)
- Testing
- Biospecimen Collection, Educational Intervention, Exercise Intervention
- Where
- 6 sites in United States
- Volunteers
- 164 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer, Breast Cancer Stage II
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
This purpose of this study is to examine skin reactions (called radiation dermatitis) that occur during pencil beam scanning (PBS) proton therapy.
- Conditions
- Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage I
- Trial name
- NCT06006806
- Testing
- Pencil Beam Scanning Proton Therapy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Covenant Health Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Campath-1H + FK506 and Methylprednisolone for GVHD
RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00109993
- Testing
- alemtuzumab, methylprednisolone, tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Neoplasms
Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788) is an antibody-conjugated drug.
- Trial name
- NCT04983121
- Testing
- Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shengjing Hospital
Early and Locally Advanced Breast Cancer
ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness
The goal of this performance study is to learn if treatment with neoadjuvant endocrine therapy compared to chemotherapy has comparable efficacy, but better quality of life outcomes in endocrine responsive participants with early…
- Trial name
- TEODOR (NCT07084558)
- Testing
- blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived)
- Where
- 14 sites in Austria
- Volunteers
- 350 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Breast Cancer
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease
RATIONALE: Collecting and storing samples of blood and tumor tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898508
- Testing
- gene expression analysis, mutation analysis, proteomic profiling
- Where
- 3 sites in United States
- Volunteers
- 563 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, HER2 + Breast Cancer
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
The aim of this study is to evaluate the efficacy and safety of TQB2102 compared to TCbHP in the neoadjuvant treatment of HER2-positive breast cancer.
- Trial name
- NCT07136974
- Testing
- TQB2102, Docetaxel + Carboplatin + Trastuzumab +Pertuzumab
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Henan Cancer Hospital
Inflammatory Breast Cancer
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
This phase II multicentre randomized open-label study will assess the safety and efficacy of Pembrolizumab in combination with standard chemotherapy in inflammatory breast cancer.
- Trial name
- PELICAN (NCT03515798)
- Testing
- Pembrolizumab Injection, neoadjuvant EC-paclitaxel chemotherapy
- Where
- 12 sites in France
- Volunteers
- 52 people
- Sponsor
- Institut Paoli-Calmettes
Brain Metastases
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.
- Trial name
- NCT00538343
- Testing
- berubicin hydrochloride (RTA 744)
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Biogen
Breast Cancer
S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission
RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of…
- Trial name
- NCT00227474
- Testing
- recombinant modified vaccinia Ankara-5T4 vaccine, adjuvant therapy, recombinant viral vaccine therapy
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.